This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2015 by Tel-Aviv Sourasky Medical Center
Information provided by (Responsible Party):
Tel-Aviv Sourasky Medical Center Identifier:
First received: November 12, 2012
Last updated: March 25, 2015
Last verified: March 2015
The purpose of this study is to determine whether ranolazine will reduce the risk of arrhythmic events in patients with long QT syndrome type 3.

Condition Intervention Phase
Long QT Syndrome Type 3 Drug: Ranolazine Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • Number of participants with syncope and/or documented ventricular arrhythmia [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • Change in corrected QT interval [ Time Frame: within 30 days of initiation of Ranolazine treatment ]

Estimated Enrollment: 10
Study Start Date: October 2012
Estimated Study Completion Date: November 2017
Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ranolazine
Ranolazine 500-1000 mg twice a day as tolerated
Drug: Ranolazine
Other Name: Ranexa


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Long QT patients with genetic confirmation of carrier-status for the D1790G mutation in the SCN5A gene
  • Corrected QT interval > 460 msec

Exclusion Criteria:

  • Need for therapy with medications that are potent or moderately potent CYP3A inhibitors (such as ketoconazole, diltiazem, verapamil, macrolide antibiotics or HIV protease inhibitors)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01728025

Contact: Sami Viskin, MD 972-3-6973311
Contact: Jesaia Benhorin, MD 972-3-6973311

Tel Aviv Medical Center Recruiting
Tel Aviv, Israel
Contact: Sami Viskin, MD    972-3-6973311   
Principal Investigator: Sami Viskin, MD         
Sub-Investigator: Jesaia Benhorin, MD         
Sub-Investigator: Arnon Adler, MD         
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Tel-Aviv Sourasky Medical Center Identifier: NCT01728025     History of Changes
Other Study ID Numbers: TASMC-12-SV-0363-10-CTIL
Study First Received: November 12, 2012
Last Updated: March 25, 2015

Keywords provided by Tel-Aviv Sourasky Medical Center:
Long QT syndrome

Additional relevant MeSH terms:
Long QT Syndrome
Pathologic Processes
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Heart Defects, Congenital
Cardiovascular Abnormalities
Congenital Abnormalities
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action processed this record on September 19, 2017